Author Interviews, Breast Cancer, JAMA, MD Anderson / 08.10.2013

Kelly K. Hunt, MD F.A.C.S. Professor, Department of Surgical Oncology, Division of Surgery Chief, Breast Surgical Oncology Section, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TXMedicalResearch.com Interview with: Kelly K. Hunt, MD F.A.C.S. Professor, Department of Surgical Oncology, Division of Surgery Chief, Breast Surgical Oncology Section, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX MedicalResearch.com: What are the main findings of the study? Dr. Hunt: We found that 40% of women who had node positive disease at initial presentation (confirmed by needle biopsy) had no evidence of residual cancer in the lymph nodes after chemotherapy. We performed sentinel lymph node (SLN) surgery followed by axillary lymph node dissection in all of the patients and found a false negative rate of 12.6% with the SLN procedure. The false negative rate was lower when surgeons used two mapping agents (blue dye and radioisotope) to identify the sentinel nodes and when they removed more than 2 sentinel nodes.
Author Interviews, Breast Cancer, Cancer Research, Lancet / 20.09.2013

Prof Aron Goldhirsch Department of Medicine European Institute of Oncology Via Ripamonti 435, 20141 Milan, ItalyMedicalResearch.com Interview with: Prof Aron Goldhirsch Department of Medicine European Institute of Oncology Via Ripamonti 435, 20141 Milan, Italy MedicalResearch.com: What are the main findings of the study? Prof. Goldhirsch:  Two years of adjuvant trastuzumab after standard chemotherapy is not more effective than is 1 year of treatment with the drug for patients with HER2-positive early breast cancer.
Author Interviews, Breast Cancer, Lancet / 20.09.2013

Prof John R Yarnold Division of Radiotherapy and Imaging The Royal Marsden NHS Foundation Trust Sutton, Surrey SM2 5PT, UKMedicalResearch.com Interview with: Prof John R Yarnold Division of Radiotherapy and Imaging The Royal Marsden NHS Foundation Trust Sutton, Surrey SM2 5PT, UK   MedicalResearch.com: What are the main findings of the study? Prof. Yarnold: A 3-week schedule of curative post-operative radiotherapy for women with breast cancer involving 15 treatments (fractions) delivered Monday to Friday each week, is at least as safe and effective as historical schedules given over 5 or 6 weeks. In fact the 3-week schedule is gentler on the healthy tissues than earlier standard regimens.
Author Interviews, Breast Cancer, MRI / 13.09.2013

Nariya Cho, MD Departments of Radiology Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.MedicalResearch.com Interview with: Nariya Cho, MD Departments of Radiology Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.   MedicalResearch.com: What are the main findings of the study? Dr. Cho: Smaller reduction in tumor volume and a smaller reduction in washout component on dynamic contrast agent–enhanced MR imaging assessed by computer-aided evaluation after neoadjuvant chemotherapy were independent parameters of worse recurrence-free survival and overall survival in breast cancer patients who received neoadjuvant chemotherapy.
Alcohol, Author Interviews, Breast Cancer, JNCI, OBGYNE / 30.08.2013

MedicalResearch.com Interview with: Ying Liu, MD, PhD Instructor, Division of Public Health Sciences Department of Surgery Washington University School of Medicine 660 South Euclid Ave Campus Box 8100 St. Louis, MO 63110 MedicalResearch.com: What are the main findings of the study? Answer: Alcohol intake between menarche (first menstrual period) and first pregnancy was consistently associated with increased risks of breast cancer and proliferative benign breast disease. For every 10 gram/day alcohol intake (approximately a drink a day) during this specific time period, the risk for breast cancer increased by 11% and the risk for proliferative benign breast disease increased by 16%.
Author Interviews, Breast Cancer, Cancer Research / 23.08.2013

Solveig Hofvind, PhD Cancer Registry of Norway, Oslo and Akershus University College of Applied Sciences, Majorstua 0403, Oslo, NorwayMedicalResearch.com Interview with: Solveig Hofvind, PhD Cancer Registry of Norway, Oslo and Akershus University College of Applied Sciences, Majorstua 0403, Oslo, Norway MedicalResearch.com: What are the main findings of the study? Dr. Hofvind: We find that if 100 women aged 50 years attend the Norwegian Breast Cancer Screening Program as recommended, every two years until they are 69 years, four women will undergo a needle biopsy with benign outcome (a false positive needle biopsy). In the same group of women, twenty women will be recalled for further examination and have additional imaging, ultrasound, and/or a biopsy with negative outcome (a false positive screening result).
Author Interviews, Bone Density, Breast Cancer, Mineral Metabolism / 23.08.2013

Richard R. Love, MD MS International Breast Cancer Research Foundation Professor of Medicine and Public Health The Ohio State University Columbus, OHMedicalResearch.com: Interview with: Richard R. Love, MD MS International Breast Cancer Research Foundation Professor of Medicine and Public Health The Ohio State University Columbus, OH MedicalResearch.com: What are the main findings of the study? Answer: Surgical oophorectomy and tamoxifen treatment was associated with no loss of bone mineral density (BMD) in the femoral neck, and loss of BMD in the first year, followed by stabilization in the lumbar spine.
Author Interviews, Breast Cancer, Genetic Research / 20.08.2013

Steven A. Narod, MD Women’s College Research Institute 790 Bay St, 7th Floor Toronto, ON, M5G 1N8 CanadaMedicalResearch.com Author Interview: Steven A. Narod, MD Women’s College Research Institute 790 Bay St, 7th Floor Toronto, ON, M5G 1N8 Canada MedicalResearch.com: What are the main findings of the study? Answer: We found that the survival of women with breast cancer and a brca1 mutation was similar to that of women with breast cancer and no mutation.
Author Interviews, Breast Cancer, Johns Hopkins, Stem Cells / 13.08.2013

Harvard Stem Cell Institute's Kornelia Polyak, MD, PhD, MedicalResearch.com Interview with: Kornelia Polyak, MD, PhD Professor of Medicine Dana-Farber Cancer Institute Harvard Medical School Boston, MA 02215 MedicalResearch.com: What are the main findings of the study? Dr. Polyak: We found that when comparing normal breast tissue of women who have not had children (nulliparous) and those who had children in their early 20s, the largest changes are in breast epithelial progenitors. The frequency of these cells is lower in parous women (women who had children) and the properties are also altered in a way that they are less likely to proliferate. Women with high risk of breast cancer, such as BRCA1 and BRCA2 mutation carriers, have very high frequency of these cells, and also parous women who did get cancer have more than those who did not. These results indicate that the frequency of these cells may predict breast cancer risk.
Author Interviews, Breast Cancer, Race/Ethnic Diversity / 07.08.2013

MedicalResearch.com Interview with: Lindsey Enewold PhD, MPH Division of Military Epidemiology and Population Sciences John P. Murtha Cancer Center Walter Reed National Military Medical Center Rockville, Maryland MedicalResearch.com: What are the main findings of the study?
 Answer: With increasing time since breast cancer diagnosis women were less likely to receive surveillance mammography. Minority women were equally or more likely than non-Hispanic white women to receive surveillance mammography within an equal access healthcare system.
Author Interviews, Breast Cancer, Radiology, Yale / 30.07.2013

MedicalResearch.com Interview with Dr. Brian Haas MD Department of Diagnostic Radiology,Yale University School of Medicine, New Haven, CT Dr. Brian Haas MD Department of Diagnostic Radiology,Yale University School of Medicine, New Haven, CT MedicalResearch.com: What are the main findings of the study? Dr. Haas: We found that tomosynthesis helped to reduce the number of women who undergo a screening mammogram and are called back for additional imaging and testing. Specifically, the greatest reductions in patients being called back were seen in younger patients and those with dense breasts. Tomosynthesis is analogous to a 3D mammogram, and improves contrast of cancers against the background breast parenchyma.
Author Interviews, Breast Cancer, Cancer Research, Radiology, Yale / 01.07.2013

MedicalResearch.com Interview with: Sarah H. O'Connell M.D. PGY-4 Yale New Haven Hospital Yale School of Medicine Department of Diagnostic Radiology MedicalResearch.com:  What are the main findings of the study? Answer: The purpose of our study was to evaluate the visibility of cancers in women at high-risk for breast cancer on 2D mammography compared to digital breast tomosynthesis. In other words, how would the use of tomosynthesis contribute to cancer visualization in this population  of patients? We evaluated the cancers seen in both high-risk patients, those with a >20% lifetime risk of breast cancer, and intermediate risk  patients, those with a 15-20% lifetime risk of breast cancer, for a total of 56 cancers. We found that 41% (23/56) cancers were better seen on tomosynthesis and 4% (2/56) were only seen on tomosynthesis. The majority of the cancers seen better or only on tomosynthesis  presented as masses rather than as calcifications alone which were better seen on 2D mammography.
Author Interviews, BMJ, Breast Cancer, Cancer Research, Fish, Nutrition / 28.06.2013

MedicalResearch.com Interview with Duo Li (PhD, MSc, BMed) Co-Editor, Asia Pacific Journal of Clinical Nutrition Associate Editor, Journal of Nutrigenetics & Nutrigenomics Professor of Nutrition Dept. of Food Science & Nutrition Zhejiang University 866 Yu-Hang-Tang Road Hangzhou 310058, China MedicalResearch.com: What are the main findings of the study? Dr. Li: The main finding is that intake marine n-3 polyunsaturated fatty acids (n-3 PUFAs) from both fish and fish oil lower the risk of breast cancer. Women with a high intake of marine n-3 PUFAs had a 14-percent reduction in risk of breast cancer compared with those who had a low intake. Every 0.1 g increase in marine n-3 PUFA per day was linked to a five-percent reduction in breast cancer risk.
Author Interviews, Breast Cancer, Genetic Research, PNAS / 03.04.2013

MedicalResearch.com eInterview with Dr. Mathieu Lupien PhD Dr. Mathieu Lupien PhD Princess Margaret Cancer Centre, University Health Network Ontario Cancer Institute (OCI) Assistant Professor Department of Medical Biophysics University of Toronto Princess Margaret Cancer Centre, University Health Network Ontario Cancer Institute (OCI) Assistant Professor Department of Medical Biophysics University of Toronto MedicalResearch.com: What are the main findings of the study? Dr. Lupien: Approximately 50% of breast cancer patients fail to respond to the standard of care based on endocrine (hormonal) therapy. Our research identifies a mechanism that accounts for this resistance. Drugs against this mechanism are already tested for other diseases. Hence, our discovery should rapidly help reposition these drugs against endocrine therapy resistant breast cancer.
Author Interviews, Breast Cancer, Cancer Research, Depression, Mental Health Research / 28.03.2013

MedicalResearch.com Interview with Mylin A. Torres, M.D. Assistant Professor Department of Radiation Oncology Emory University School of Medicine Atlanta, GA 30322 MedicalResearch.com: What are the main findings of the study?  Dr. Torres: Radiation treatment for breast cancer is not associated with increased depressive symptoms, but of disease and treatment-related factors, prior chemotherapy treatment is a significant predictor of depression before and after radiation treatment.  Prior chemotherapy treatment was associated with inflammatory mediators, including nuclear factor-kappa B DNA binding, soluble tumor necrosis factor-alpha receptor 2, and interleukin-6, which predicted for depressive symptoms after radiation on univariate analysis.
Thank you for visiting MedicalResearch.com Senior Editor, Marie Benz MD. For more information please email: info@MedicalResearch.com

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.